Replimune's RP1: Strong Refractory Melanoma Data Meets High Regulatory Bar of Prior Rejection and Single-Arm Design

FDA Recommits to Advisory Committees for Rejected Therapies

The FDA is significantly increasing its advisory committee (adcomm) meetings, reversing a previous curtailment under new leadership. This shift is evident with scheduled adcomms for previously rejected investigational therapies, including Replimune's RP1 for advanced melanoma and Capricor Therapeutics' deramiocel for Duchenne muscular dystrophy cardiomyopathy. While the agency aims to leverage these committees as valuable scientific resources, industry leaders express concerns about ensuring the right subject matter experts are present to facilitate rigorous scientific discussions, rather than merely fulfilling a procedural requirement, especially given the complexities of some therapies.

• FDA's Renewed Emphasis on Advisory Committees: Following a nine-month drought, the FDA has recommitted to holding advisory committee meetings, a change attributed to new leadership, including Interim Commissioner Kyle Diamantas and acting CBER head Karim Mikhail. They advocate for more adcomms, viewing them as crucial scientific resources to advance public health, contrasting with the previous administration's skepticism and curtailment of such meetings. This signals a significant shift in the agency's approach to regulatory review and expert consultation.
• Review of Previously Rejected Therapies: The upcoming adcomms will specifically revisit therapies that have faced prior rejections. This includes Replimune's RP1, an advanced melanoma drug that was twice rebuffed, and Capricor's deramiocel, a cell therapy for Duchenne muscular dystrophy cardiomyopathy that received a Complete Response Letter. Both companies have since resubmitted their applications, with Replimune's PDUFA date set for August 2, highlighting the agency's willingness to re-evaluate complex cases.
• Concerns Over Adcomm Composition and Purpose: Industry and regulatory experts, including former FDA officials, are questioning the rationale and composition of the newly scheduled adcomms. They stress the critical importance of having appropriate subject matter experts on these committees to ensure high-standard scientific discussions and avoid perfunctory reviews. Concerns are particularly heightened for complex areas like Duchenne muscular dystrophy, where past controversial decisions underscore the need for rigorous, informed deliberation rather than merely "checking a box."

Addressing Persistent Challenges in Advanced Melanoma Treatment

Despite significant advances in targeted therapy and immunotherapy, advanced melanoma treatment continues to face substantial obstacles related to resistance, toxicity, and patient selection. These limitations underscore the need for more durable, personalized, and better-tolerated treatment strategies across multiple therapeutic modalities.

• Drug resistance remains pervasive, affecting BRAF inhibitors, MEK inhibitors, and immune checkpoint inhibitors alike, with most patients ultimately developing progressive disease despite initial responses to targeted or immune-based therapies.

• A substantial subset of patients fails to respond to either BRAF inhibitors or immune checkpoint inhibitors, and even among initial responders, a remarkable proportion develop resistance—even when MEK inhibitors are added to the regimen.

• Low response rates persist with PD-1/PD-L1 and CTLA-4 axis inhibitors, compounded by significant treatment-related toxicities associated with these checkpoint inhibitor classes.

• Heterogeneous response patterns complicate immunotherapy outcomes, making it difficult to predict which patients will achieve durable benefit.

• Chemical/chemotherapeutic treatments continue to show poor medication response and high rates of resistance, while surgical resection and chemo/targeted therapy approaches are limited by metastatic spread and acquired drug resistance.

• CAR-T cell therapy has underperformed in melanoma relative to its success in hematologic malignancies, with ongoing research needed to address challenges posed by the tumor microenvironment and antigen specificity.

• Reliable predictive biomarkers are lacking, hampering clinicians' ability to select appropriate patients and anticipate treatment response.

• Critical clinical questions remain unresolved regarding optimal treatment combinations, sequencing, and personalization strategies.

• Long-term toxicity management is an emerging concern as treatment indications broaden and patient populations eligible for therapy expand, necessitating greater attention to survivorship issues.

RP1's Place in the Evolving Advanced Melanoma Landscape

The treatment landscape for advanced melanoma has been revolutionized over the past five years, primarily driven by the success of immune checkpoint inhibitors (ICIs). Therapies targeting PD-1, such as pembrolizumab and nivolumab, and the anti-CTLA-4 antibody ipilimumab, now form the standard of care. This shift has produced unprecedented improvements in long-term survival; where five-year survival rates were once below 5%, they now exceed 50% for patients with advanced disease. Long-term follow-up data has confirmed the durability of these responses, with the combination of nivolumab and ipilimumab demonstrating a median overall survival surpassing 70 months. The application of immunotherapy has also expanded into earlier disease stages, with practice-changing data supporting the use of ICIs in the neoadjuvant setting for resectable macroscopic disease and as adjuvant therapy for resected stage IIB, IIC, and III melanoma to improve relapse-free survival.

Building on the foundation of initial ICI monotherapies, recent advancements have focused on novel combinations and new therapeutic modalities. The introduction of new ICIs, such as the LAG-3 inhibitor relatlimab, has added further complexity and options to first-line treatment decisions. For patients with BRAF-mutant melanoma, clinical evidence now suggests that initiating treatment with ICI therapy provides a greater survival benefit compared to starting with BRAF/MEK inhibitor therapy. Furthermore, the field is advancing with innovative approaches like adoptive cell therapy. In a pivotal Phase 3 trial for patients with disease refractory to anti-PD-1 treatment, tumor-infiltrating lymphocyte (TIL) therapy demonstrated a median progression-free survival of 7.2 months versus 3.1 months for ipilimumab and a median overall survival of 25.8 months versus 18.9 months. Other emerging strategies include oncolytic viruses, which can modulate the tumor microenvironment to enhance ICI efficacy, and the FDA approval of agents like tebentafusp and lifileucel, which are extending survival for patients with rare subtypes like metastatic uveal melanoma.

Despite this significant progress, substantial challenges persist in the management of advanced melanoma. Approximately half of all patients either do not respond to initial therapy or experience early or late relapse, with primary and acquired resistance remaining the principal causes of treatment failure. The limitations of current ICI regimens, including low response rates in certain patient subsets, the development of resistance, and treatment-related toxicities, underscore a significant ongoing unmet medical need. These challenges highlight the critical importance of developing more effective combination strategies, identifying predictive biomarkers, and exploring novel mechanisms of action to overcome resistance and extend durable clinical benefits to a broader population of patients.